Aura Competitors

Stocks . USA . 
Stock . Aura Biosciences
AURA Stock  USD 5.68  0.06  1.05%   
Aura Biosciences competes with EnGene Holdings, LB Pharmaceuticals, Altimmune, QuantumSi, and Rocket Pharmaceuticals; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Aura Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Aura Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Aura Biosciences Correlation with its peers.
For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.

Aura Biosciences vs Solid Biosciences Correlation

Weak diversification

The correlation between Aura Biosciences and SLDB is 0.33 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Aura Biosciences and SLDB in the same portfolio, assuming nothing else is changed.

Moving against Aura Stock

  0.65GE GE AerospacePairCorr
  0.56CVX Chevron Corp Earnings Call This WeekPairCorr
  0.43XOM Exxon Mobil Corp Earnings Call This WeekPairCorr
  0.42AA Alcoa CorpPairCorr
  0.41BA Boeing Earnings Call This WeekPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.335.689.03
Details
Intrinsic
Valuation
LowRealHigh
2.155.508.85
Details
Naive
Forecast
LowNextHigh
2.836.189.53
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
4.775.446.10
Details

Aura Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Aura Biosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Aura and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Aura Biosciences does not affect the price movement of the other competitor.

High positive correlations

ANNX
+ 0.85
LBRX
ANNX
+ 0.84
DSGN
DSGN
+ 0.82
LBRX
SLDB
+ 0.8
LBRX
SLDB
+ 0.75
ANNX
ANNX
+ 0.72
ENGN
  

High negative correlations

KRRO
- 0.75
DSGN
KRRO
- 0.58
ANNX
KRRO
- 0.5
LBRX
DSGN
- 0.42
QSI
KRRO
- 0.42
ENGN
KRRO
- 0.38
ALT

Risk-Adjusted Indicators

There is a big difference between Aura Stock performing well and Aura Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aura Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ENGN  4.44  0.83  0.19  0.75  3.94 
(5.71)
 11.36 
(5.79)
 61.40 
LBRX  3.81  0.68  0.16  5.39  3.41 
(4.71)
 9.38 
(6.59)
 23.59 
ALT  3.64  0.60  0.11 (10.77) 4.35 
(4.77)
 9.22 
(4.73)
 33.75 
QSI  3.61 (1.22) 0.00 (0.32) 0.00 
 0.00 
 6.50 
(8.33)
 15.95 
RCKT  2.99 (0.10) 0.00 (0.03) 0.00 
 0.00 
 8.04 
(5.57)
 16.20 
DSGN  3.56  0.67  0.16  1.59  3.56 
(4.03)
 9.28 
(5.98)
 18.90 
ANNX  4.28  1.30  0.28 (0.86) 3.33 
(5.52)
 11.30 
(7.54)
 35.10 
KRRO  5.25 (0.64) 0.00  0.57  0.00 
 0.00 
 10.98 
(6.62)
 91.55 
DBVT  4.13  0.82  0.17 (1.53) 3.69 
(5.14)
 10.53 
(6.66)
 36.36 
SLDB  3.80  0.23  0.05  0.26  4.48 
(4.52)
 11.36 
(7.56)
 21.63 

Aura Biosciences Competitive Analysis

The better you understand Aura Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Aura Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Aura Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AURA ENGN LBRX ALT QSI RCKT DSGN ANNX KRRO DBVT
 1.05 
 5.68 
Aura
 14.38 
 12.17 
EnGene
 1.40 
 23.91 
LBRX
 2.23 
 5.50 
Altimmune
 4.58 
 1.25 
QuantumSi
 1.59 
 3.72 
Rocket
 4.14 
 10.18 
Design
 2.59 
 6.78 
Annexon
 2.09 
 10.73 
Frequency
 6.51 
 24.54 
DBV
Market Volatility
(90 Days Market Risk)
Slightly risky
Moderately volatile
Somewhat reliable
Risky
Dangerous
Unstable
Slightly risky
Unstable
Unstable
Not too volatile
Market Performance
(90 Days Performance)
Weakest
Fair
Good
Fair
Weakest
Weakest
Good
Solid
Weakest
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Low
Strong
Small
Small
Small
Moderate
Low
Risky
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Buy
Not Available
Not Available
Not Available
Not Available
Buy
Trade Advice
(90 Days Macroaxis Advice)
Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Current Ratio
21.97
N/A
N/A
14.12
35.44
13.41
48.96
8.95
N/A
8.54
Net Asset
182.5 M
221.47 M
33.53 M
139.31 M
247.87 M
527.7 M
252.09 M
350.07 M
226.24 M
65.66 M
EBITDA
(94.89 M)
(113.8 M)
(63.01 M)
(94.81 M)
(103.98 M)
(247.49 M)
(48.99 M)
(134.75 M)
(88.34 M)
(110.99 M)
Current Valuation
216.59 M
653.26 M
N/A
379.01 M
48.13 M
204.87 M
375.66 M
875.65 M
51.07 M
1.3 B
Price To Book
2.3
4.86
N/A
3.09
1.15
1.28
2.9
6.43
1.0
25.21
Operating Margin
N/A
N/A
N/A
N/A
-44.2
N/A
N/A
N/A
-17.65
-12.36
Retained Earnings
(374.23 M)
(372.03 M)
(104.32 M)
(561.39 M)
(596.64 M)
(1.22 B)
(227.21 M)
(710.7 M)
(266.59 M)
(286.38 M)
Current Asset
N/A
N/A
N/A
13.9 M
N/A
N/A
N/A
N/A
N/A
334.89 M
One Year Return
N/A
4.07
N/A
-6.49
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.46
-0.28
N/A
0.03
3.03
0.47
1.64
1.19
2.53
-0.41
Number Of Employees
106
81
16
59
149
299
55
99
87
117
Equity Positions Weight
N/A
N/A
N/A
21.57
N/A
N/A
N/A
N/A
N/A
N/A
Shares Outstanding
63.5 M
66.98 M
N/A
104.34 M
195.55 M
108.22 M
56.96 M
149.06 M
9.42 M
54.29 M
Three Year Return
N/A
3.14
N/A
-0.57
N/A
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(79.81 M)
(99.24 M)
(53.05 M)
(79.85 M)
(87.8 M)
(209.72 M)
(43.1 M)
(118.01 M)
(60.07 M)
(104.47 M)
Total Debt
18.77 M
31.8 M
3.7 M
1.68 M
12.95 M
25.5 M
2.33 M
28.97 M
44.77 M
7.8 M
Return On Equity
-0.64
-0.53
N/A
-0.53
-0.52
-0.75
-0.3
-0.84
-0.63
-2.34
Bond Positions Weight
N/A
97.03
N/A
15.26
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.36
-0.29
N/A
-0.31
-0.27
-0.41
-0.2
-0.45
-0.29
-0.77
Number Of Shares Shorted
3.17 M
1.5 M
N/A
25.81 M
19.26 M
12.74 M
2.23 M
16.28 M
1.11 M
891.49 K
Book Value Per Share
2.49
3.22
N/A
1.94
1.09
2.9
3.51
1.4
10.54
0.39
Current Liabilities
N/A
N/A
N/A
10.49 M
N/A
N/A
N/A
N/A
N/A
16.02 M
Total Asset
182.5 M
221.47 M
33.53 M
139.31 M
247.87 M
527.7 M
252.09 M
350.07 M
226.24 M
65.66 M
Debt To Equity
0.005
N/A
N/A
0.006
0.041
0.057
0.011
0.2
N/A
0.016
Short Ratio
17.67
5.52
N/A
5.49
4.09
6.51
4.45
5.83
3.36
1.2
Target Price
19.4
23.5
N/A
17.75
2.68
7.65
14.4
14.33
8.67
40.3
Shares Owned By Institutions
84.36
77.91
N/A
40.25
30.57
90.1
58.93
79.5
93.85
13.05
Market Capitalization
360.7 M
815.2 M
N/A
573.88 M
269.36 M
402.59 M
579.89 M
1.01 B
101.05 M
1.33 B
Price To Earning
N/A
N/A
N/A
-1.66
5.15
N/A
N/A
N/A
N/A
-8.25
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
0.03
N/A
-0.04
N/A
N/A
Price To Sales
N/A
N/A
N/A
28694.16
84.79
N/A
22642.01
N/A
13.71
242.16
Net Income
(86.92 M)
(117.3 M)
(63.1 M)
(95.06 M)
(101.01 M)
(258.75 M)
(49.59 M)
(138.2 M)
(83.58 M)
(113.92 M)
Earnings Per Share
-1.91
-2.29
N/A
-1.07
-0.67
-2.25
-1.19
-1.41
-9.42
-5.2
Shares Owned By Insiders
1.87
0.09
N/A
0.65
11.61
3.68
35.96
0.33
6.15
N/A
Year To Date Return
N/A
-0.98
N/A
1.67
N/A
N/A
N/A
N/A
N/A
N/A
Revenue
N/A
N/A
N/A
20 K
3.06 M
N/A
N/A
N/A
2.27 M
2.57 M
Working Capital
145.71 M
169.41 M
20.77 M
126.79 M
199.82 M
337.5 M
239.58 M
285.95 M
116.57 M
13.25 M
Cash And Equivalents
122.13 M
N/A
N/A
184.76 M
400.67 M
321.37 M
359.38 M
177.59 M
N/A
247.97 M
Cash Per Share
4.17
N/A
N/A
3.81
2.88
4.87
6.45
3.73
N/A
1.32
Gross Profit
N/A
N/A
N/A
(67.78 M)
1.64 M
N/A
(57.86 M)
N/A
46 K
5.5 M
Day Typical Price
5.66
11.64
23.79
5.76
1.27
3.77
10.42
6.91
10.62
24.56
Accumulation Distribution
0.045
0.14
0.0593
0.17
0.0606
0.0514
0.0775
0.0585
0.0677
0.065
Market Facilitation Index
0.26
1.76
1.45
1.1
0.08
0.2
0.85
0.42
0.74
1.65
Daily Balance Of Power
(0.23)
0.8693
0.2276
0.1091
(0.75)
(0.30)
(0.52)
(0.43)
0.2973
0.9091
Period Momentum Indicator
(0.06)
1.53
0.33
0.12
(0.06)
(0.06)
(0.44)
(0.18)
0.22
1.5
Rate Of Daily Change
0.99
1.14
1.01
1.02
0.95
0.98
0.96
0.97
1.02
1.07
Day Median Price
5.65
11.37
23.74
5.89
1.28
3.79
10.55
6.97
10.56
24.58
Price Action Indicator
N/A
1.56
0.34
(0.33)
(0.06)
(0.10)
(0.58)
(0.28)
0.28
0.71
Relative Strength Index
49.16
69.87
60.6
64.3
40.99
50.94
58.09
66.55
35.36
66.11
Coefficient Of Variation
(5,530)
829.09
717.33
901.71
(454.85)
(20,040)
639.38
484.82
(1,592)
776.49
Mean Deviation
2.37
4.44
3.81
3.64
3.61
2.99
3.56
4.28
5.25
4.13
Jensen Alpha
(0.12)
0.8336
0.683
0.6048
(1.22)
(0.1)
0.6731
1.3
(0.64)
0.8233
Total Risk Alpha
(0.38)
0.1996
0.2218
0.0867
(1.43)
(0.39)
0.2776
0.6548
(1.79)
0.2096
Sortino Ratio
N/A
0.1861
0.1598
0.1072
N/A
N/A
0.1561
0.2774
N/A
0.1705
Downside Variance
N/A
20.8
15.21
24.7
N/A
N/A
16.56
16.78
N/A
17.83
Standard Deviation
3.35
7.69
5.03
5.51
4.53
3.88
4.56
5.89
11.38
6.2
Kurtosis
2.15
20.1
0.7094
5.87
(0.61)
0.2198
(0.08)
4.75
38.25
4.99
Potential Upside
4.74
11.36
9.38
9.22
6.5
8.04
9.28
11.3
10.98
10.53
Treynor Ratio
(0.09)
0.749
5.39
(10.77)
(0.32)
(0.03)
1.59
(0.86)
0.5706
(1.53)
Maximum Drawdown
18.08
61.4
23.59
33.75
15.95
16.2
18.9
35.1
91.55
36.36
Variance
11.24
59.11
25.34
30.35
20.52
15.05
20.81
34.67
129.43
38.4
Market Risk Adjusted Performance
(0.08)
0.759
5.4
(10.76)
(0.31)
(0.02)
1.6
(0.85)
0.5806
(1.52)
Risk Adjusted Performance
(0.01)
0.0974
0.1106
0.0899
(0.15)
0.0045
0.1229
0.1598
(0.04)
0.1031
Skewness
0.8818
3.52
0.7525
(0.28)
0.1825
0.495
0.4438
1.48
(5.45)
1.68
Semi Deviation
N/A
3.94
3.41
4.35
N/A
N/A
3.56
3.33
N/A
3.69
Information Ratio
(0.04)
0.1104
0.1238
0.0967
(0.24)
(0.03)
0.1392
0.193
(0.07)
0.1161
Value At Risk
(5.34)
(5.79)
(6.59)
(4.73)
(8.33)
(5.57)
(5.98)
(7.54)
(6.62)
(6.66)
Expected Short fall
N/A
(5.71)
(4.71)
(4.77)
N/A
N/A
(4.03)
(5.52)
N/A
(5.14)
Downside Deviation
N/A
4.56
3.9
4.97
N/A
N/A
4.07
4.1
N/A
4.22
Semi Variance
N/A
15.54
11.63
18.89
N/A
N/A
12.64
11.08
N/A
13.59

Aura Biosciences Competition Performance Charts

Five steps to successful analysis of Aura Biosciences Competition

Aura Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Aura Biosciences in relation to its competition. Aura Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Aura Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Aura Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Aura Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Aura Biosciences position

In addition to having Aura Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Diversified Assets Thematic Idea Now

Diversified Assets
Diversified Assets Theme
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Aura Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aura Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aura Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aura Biosciences Stock:
How To Invest In Aura
Details
Is Aura Stock a good investment?
Details
What is Aura Biosciences' Net Worth?
Details
Largest Stock Exchange Of Companies
View
Top Sectors
View
Check out Aura Biosciences Correlation with its peers.
For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Aura Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY